Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CCS Cell Culture Service and Cytocentrics Agree Cooperation in the Field of Cell Line Development

Published: Monday, October 06, 2008
Last Updated: Monday, October 06, 2008
Bookmark and Share
The agreement is aimed at the development of electrophysiologically optimized ion channel cell lines which allow a reliable testing of substances and drugs.

Biotechnology companies CCS Cell Culture Service GmbH and Cytocentrics AG has announced the signing of a research and license agreement. The aim of the cooperation is to develop electrophysiologically optimized ion channel cell lines which allow a reliable testing of substances and drugs.

The pharmaceutical industry depends on suitable in-vitro test methods for preclinical drug screening and safety pharmacology testing. Over recent years the automated patch clamp technology has established itself in this field. However, in many cases the application of conventional recombinant cell lines results in low data quality.

The cooperation paves the way for the production of cell lines generating reliable and reproducible data in automated patch clamp systems. CCS brings its expertise in the production of recombinant cell lines into this partnership and Cytocentrics will focus on electrophysiological optimization.

"Combining the core competences of both companies will set new standards in the development of new drugs", explains Dr. Oliver Klotzsche, managing director and co-founder of the CCS Cell Culture Service GmbH. "Both companies have very high quality standards. The long experience of both companies allows professional work to be carried out in compliance with the high standards required by the pharmaceutical industry".

In detail the cooperation agreement comprises the production and optimization of cell lines expressing pharmacologically relevant ion channels. The first two cell lines hERG-HEK 293 and hNav1.5-CHO have recently become available for purchase.

“In our service sector for safety pharmacology testing, we are already successfully using cell lines which have been jointly developed", explains Dr. Christa Nutzhorn, President of Cytocentrics AG. “Customers from the pharmaceutical industry sector are completely satisfied with the high quality of measuring data."

Each batch of cells is subjected to quality controls prior to delivery. Quality standards refer to the seal rate, rate of whole-cell recordings, stability and existence of a homogenous flow. Customers can either acquire a license for a cell line or order so-called "Instant Cells", rendering unnecessary the time consuming cultivation of cells. These cells are ready-to-use in an assay within 15 minutes after defrosting.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!